Global Mycoplasma Testing Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation & Forecast 2024

Published - Apr 2019 | Category - Healthcare | No. of Pages - 146 | Published By - EMR


The Global Mycoplasma Testing Market was valued at USD 606.9 million in 2017, and is expected to reach USD 1358.2 million by 2024, at a augmenting CAGR of 12.3% during 2018-2024.

The demand for mycoplasma testing in biopharmaceutical sector is on the rise as mycoplasma contaminates the cell culture and affects the entire production batch. The bacteria grow in cell culture media and can reach very high numbers without causing visible changes in the culture while affecting cell cultures (changes in metabolism, biochemical or immunologic properties, growth, and viability). The mycoplasma testing offers revolutionary opportunities for pharmaceutical and biotechnology companies. To minimize the financial risk and maintain product quality, manufactures collect thousands of samples for sterility and bioburden testing every year. With Increasing research and development activities and growing demand for biopharmaceutical products, regulatory bodies such as FDA and EMA are expected to increasingly approve mycoplasma testing for biopharmaceutical products in coming years.

Global Mycoplasma Testing Market Major Key Players:
Roche Diagnostics
Lonza Group Ltd
Merck KGaA
PromoCell GmbH
InvivoGen
Charles River Laboratories, Inc.
SGS SA
American Type Culture Collection
Bionique Testing Laboratories, Inc.
Biological Industries Israel Beit Haemek Ltd
Others


 

Quick Buy

Latest Publications